NEUROTECHCompleted Study | Duration: 24 Months
Phase II NEUROTECH was a multi-center, prospective, randomized clinical trial for the treatment of recurrent subfoveal choroidal neovascularization (CNV) secondary to wet Age-Related Macular Degeneration (wet AMD). The novel treatment, NT-503-3, is an anti-VEGF encapsulated cell that is implanted into the affected eye. As opposed to the current method of monthly anti-VEGF injections, NT-503-3 implantation offers a one-time procedure that delivers long-lasting, continuous anti-VEGF release. The study compared the efficacy of NT-503-3 implantation vs. intravitreal Eylea treatment, for patients who were diagnosed with wet AMD. Participants were treated and followed for two years.